lenalidomide has been researched along with Pneumonia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Certan, M; Garcia Garrido, HM; Goorhuis, A; Grobusch, MP; Heijmans, J; Wong, G | 1 |
| Finch, K; Sharma, D; Wagner, S | 1 |
| Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Kosh, M; Liu, W; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Sonneveld, P; Symeonidis, A; Terpos, E; Tran, N; Wang, J | 1 |
| Cao, Z; Tian, C; Yang, H; Zhang, Q; Zhang, Y; Zhu, L | 1 |
| Avivi, I; Cavo, M; Facon, T; Farooqui, MZH; Ghori, RU; Grigoriadis, G; Jagannath, S; Karlin, L; Kosugi, H; LeBlanc, R; Lim, ABM; Lonial, S; Marinello, P; McCroskey, RD; Oriol, A; Rifkin, RM; San-Miguel, J; Schjesvold, F; Suzuki, K; Takezako, N; Usmani, SZ; Yimer, HA | 1 |
| Amraoui, K; Belhadj, K; Dupuis, J; Jannière-Nartey, C; Maître, B | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Koureas, A; Migkou, M; Nikitas, N; Roussou, M; Terpos, E; Tsokou, E; Zagouri, F | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
2 trial(s) available for lenalidomide and Pneumonia
| Article | Year |
|---|---|
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumonia | 2023 |
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pneumonia; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2019 |
6 other study(ies) available for lenalidomide and Pneumonia
| Article | Year |
|---|---|
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Community-Acquired Infections; Disease Progression; Female; Hematologic Neoplasms; Hospitalization; Humans; Incidence; Lenalidomide; Male; Methotrexate; Pneumonia; Pneumonia, Pneumococcal; Rituximab; Thalidomide | 2022 |
Lenalidomide induced pneumonitis.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Lung; Lung Injury; Pneumonia | 2023 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Combined Modality Therapy; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pneumonia; Recombinant Fusion Proteins; Recurrence; Salvage Therapy; Syndecan-1; Thalidomide; Transplantation, Autologous | 2017 |
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Drug Administration Schedule; Fatal Outcome; Female; Humans; Iatrogenic Disease; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumonia; Thalidomide; Time Factors; Tomography, X-Ray Computed | 2013 |
Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.
Topics: Aged; Animals; Female; Humans; Immunologic Factors; Lenalidomide; Male; Mice; Middle Aged; Paraproteinemias; Pneumonia; Thalidomide | 2011 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |